enGene Therapeutics (ENGN) Morgan Stanley 24th Annual Global Healthcare Conference summary

Company overview and strategic focus

• Focuses on non-viral gene therapies to address limitations of viral approaches, such as packet size, redosability, and manufacturing challenges.

• Lead asset, detalimogene, targets non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG, with pivotal data from the LEGEND program.

• Holds $266 million in cash, supporting near-term milestones including FDA meetings and a planned U.S. filing.

• Positioned for a potential U.S. approval in 2027, with a robust clinical and manufacturing strategy.

• Designed products for ease of use in community urology practices, emphasizing low cost and simple logistics.

Market landscape and unmet need

• NMIBC is a significant disease, with 90,000 U.S. cases annually, 80% being non-muscle invasive, and 20,000–40,000 BCG-unresponsive cases each year.

• Current standard, radical cystectomy, is highly morbid, with high mortality and severe quality-of-life impacts.

• Newer agents face adoption barriers in community settings due to complexity and resource requirements.

• Community urologists have limited options, highlighting the need for accessible, effective therapies.

• Market research suggests patients are willing to try multiple lines of therapy before surgery, expanding the addressable population.

Clinical data and regulatory strategy

• Detalimogene achieved a 54% complete response (CR) rate, aligning with other approved products.

• Demonstrates best-in-class tolerability, with only 2.4% treatment discontinuation and rapid response in over 90% of patients.

• Awaiting 12-month durability data, expected later in the year, to support a BLA submission.

• Ongoing discussions with FDA on manufacturing and clinical data sufficiency, with confidence in meeting regulatory requirements.

• Statistical analysis plan under review with FDA, with potential for some patient exclusions but minimal impact on overall data strength.